Gyre TherapeuticsGYRE
About: Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Employees: 391
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
6,781% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $16K
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
34% more capital invested
Capital invested by funds: $15.1M [Q2] → $20.2M (+$5.1M) [Q3]
20% more funds holding
Funds holding: 30 [Q2] → 36 (+6) [Q3]
0.24% more ownership
Funds ownership: 1.48% [Q2] → 1.72% (+0.24%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for GYRE.